Ozagrel Sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328502

CAS#: 189224-26-8 (sodium)

Description: Ozagrel Sodium, also known as KCT-0809 and Cataclot, is a thromboxane A2 synthase inhibitor used to treat cerebrovascular diseases.

Chemical Structure

img
Ozagrel Sodium
CAS# 189224-26-8 (sodium)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 328502
Name: Ozagrel Sodium
CAS#: 189224-26-8 (sodium)
Chemical Formula: C13H11N2NaO2
Exact Mass: 0.00
Molecular Weight: 250.233
Elemental Analysis: C, 62.40; H, 4.43; N, 11.20; Na, 9.19; O, 12.79

Price and Availability

Size Price Availability Quantity
500mg USD 550
1g USD 950
2g USD 1650
Bulk inquiry

Related CAS #: 189224-26-8 (sodium)   82571-53-7 (free base),  

Synonym: Ozagrel Sodium; KCT-0809; KCT 0809; KCT0809; Cataclot; Xanbo

IUPAC/Chemical Name: sodium (E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylate

InChi Key: NCNYJCOBUTXCBR-IPZCTEOASA-M

InChi Code: InChI=1S/C13H12N2O2.Na/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;/h1-8,10H,9H2,(H,16,17);/q;+1/p-1/b6-5+;

SMILES Code: O=C([O-])/C=C/C1=CC=C(CN2C=CN=C2)C=C1.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 82571-53-7 (Ozagrel) 189224-26-8 (Ozagrel Sodium)

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Ozagrel sodium (OKY-046 sodium) is a thromboxane A2 (TXA2) synthase inhibitor.
In vitro activity: Pretreatment of blood with ozagrel, an inhibitor of TxAS, also inhibited 12-HHT and TxB2 production in a dose-dependent manner. Treatment of human platelets with 10 µM ozagrel almost completely inhibited thrombin-induced TxB2 production, and 12-HHT production was inhibited by 40–60% (Fig. 2B, supplementary Fig. III-B). Conversely, production of PGD2 and PGE2 was markedly increased by ozagrel treatment. Reference: J Lipid Res. 2013 Nov;54(11):2979-87. https://pubmed.ncbi.nlm.nih.gov/24009185/
In vivo activity: This study examined the effect of ozagrel, a thromboxane A(2) synthase inhibitor, on the accumulation of leucocytes and chemokine mRNA expression in lungs experimentally injured using oleic acid (OA). OA injection into guinea pigs rapidly increased thromboxane A(2) generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increased monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in the whole lung. Administration of ozagrel prevented these changes associated with OA injection. Reference: J Pharmacol Sci. 2009 Oct;111(2):211-5. https://pubmed.ncbi.nlm.nih.gov/19783866/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 3.6 14.49
Water 50.0 199.81

Preparing Stock Solutions

The following data is based on the product molecular weight 250.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Matsunobu T, Okuno T, Yokoyama C, Yokomizo T. Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand. J Lipid Res. 2013 Nov;54(11):2979-87. doi: 10.1194/jlr.M037754. Epub 2013 Sep 5. PMID: 24009185; PMCID: PMC3793602. 2. Ishitsuka Y, Moriuchi H, Isohama Y, Tokunaga H, Hatamoto K, Kurita S, Irikura M, Iyama K, Irie T. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111(2):211-5. doi: 10.1254/jphs.09128sc. Epub 2009 Sep 26. PMID: 19783866. 3. Imamura T, Kiguchi S, Kobayashi K, Ichikawa K, Yamazaki Y, Kojima M. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. Arzneimittelforschung. 2003;53(10):688-94. doi: 10.1055/s-0031-1299813. PMID: 14650360.
In vitro protocol: 1. Matsunobu T, Okuno T, Yokoyama C, Yokomizo T. Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand. J Lipid Res. 2013 Nov;54(11):2979-87. doi: 10.1194/jlr.M037754. Epub 2013 Sep 5. PMID: 24009185; PMCID: PMC3793602.
In vivo protocol: 1. Ishitsuka Y, Moriuchi H, Isohama Y, Tokunaga H, Hatamoto K, Kurita S, Irikura M, Iyama K, Irie T. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111(2):211-5. doi: 10.1254/jphs.09128sc. Epub 2009 Sep 26. PMID: 19783866. 2. Imamura T, Kiguchi S, Kobayashi K, Ichikawa K, Yamazaki Y, Kojima M. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. Arzneimittelforschung. 2003;53(10):688-94. doi: 10.1055/s-0031-1299813. PMID: 14650360.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Park SI, Park SK, Jang KS, Han YM, Kim CH, Oh SJ. Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model. Brain Res. 2015 Mar 2;1599:85-92. doi: 10.1016/j.brainres.2014.12.051. Epub 2014 Dec 31. PubMed PMID: 25555371.

2: Wada T, Yasunaga H, Horiguchi H, Fushimi K, Matsubara T, Nakajima S, Yahagi N. Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis. J Stroke Cerebrovasc Dis. 2016 Aug 23. pii: S1052-3057(16)30261-0. doi: 10.1016/j.jstrokecerebrovasdis.2016.07.044. [Epub ahead of print] PubMed PMID: 27567296.

3: Tange M, Yoshida M, Hazekawa M, Haraguchi T, Nakai Y, Uchida T. Prediction of compatibility between ozagrel sodium preparation for injection and calcium on the basis of the solubility product. Chem Pharm Bull (Tokyo). 2013;61(5):567-71. Epub 2013 Mar 1. PubMed PMID: 23449252.

4: Zhang J, Yang J, Chang X, Zhang C, Zhou H, Liu M. Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurol Res. 2012 May;34(4):346-53. doi: 10.1179/1743132812Y.0000000022. PubMed PMID: 22643078.

5: Yang B, Shi J, Chen X, Ma B, Sun H. Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. PLoS One. 2014 Feb 13;9(2):e88440. doi: 10.1371/journal.pone.0088440. eCollection 2014. PubMed PMID: 24551100; PubMed Central PMCID: PMC3923787.

6: Xu SH, Yin MS, Liu B, Chen ML, He GW, Zhou PP, Cui YJ, Yang D, Wu YL. Tetramethylpyrazine-2'-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion. Hum Exp Toxicol. 2016 Jul 6. pii: 0960327116657401. [Epub ahead of print] PubMed PMID: 27387348.

7: Wu H, Yu W, Huang L, Wang J, Tang X, Yang W, Liu Y, Yu H, Zhu D. Effect of sodium ozagrel on the activity of rat CYP2D6. Eur J Pharmacol. 2007 Nov 14;573(1-3):55-9. Epub 2007 Jul 4. PubMed PMID: 17651725.

8: Shinohara Y, Inoue S. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. J Stroke Cerebrovasc Dis. 2013 Jul;22(5):668-74. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.002. Epub 2012 May 22. PubMed PMID: 22622391.

9: Yao HX, Huang L, Wu CM, Lin LE, Huang ZQ, Wu JF, Wang SW, Chen WT, Tang RM. [Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1360-2. Chinese. PubMed PMID: 19840484.

10: Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 2009;27(5):485-92. doi: 10.1159/000210190. Epub 2009 Mar 26. PubMed PMID: 19321945.